A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Phase 2 Terminated 84 enrolled Merrimack Pharmaceuticals

RandomizedParallel-groupOpen-labelTreatment

To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone

Outcome not reported

Stopped: “DSMB recommendation due to lack of efficacy. There were no safety signals.”

Evaluation	Drug	Modality	Dose	Route
Subject	MM-111	Unknown	—	Intravenous
Background	Paclitaxel	Small molecule	—	Intravenous
Background	Trastuzumab	Monoclonal antibody	—	Intravenous